Högstedt S, Lindeberg S, Axelsson O, Lindmark G, Rane A, Sandström B, Lindberg B S
Acta Obstet Gynecol Scand. 1985;64(6):505-10. doi: 10.3109/00016348509156729.
In an open, controlled trial, treatment with a combination of metoprolol and hydralazine was compared with non-pharmacological management of mild and moderate hypertension in pregnancy. One hundred and sixty-one women participated in the study. The drug-treated group showed significantly better blood pressure control than the group not given antihypertensives. Induction of labor before term, because of maternal or fetal complications, was somewhat more frequent in the control group. Nine women in the treatment group and 5 in the control group developed albuminuria. Three infants in the drug-treated group died perinatally, and one in the control group. The outcome for the newborns was similar in both groups concerning birth weight, head circumference and Apgar score and in the frequencies of respiratory distress, bradycardia and hypoglycemia. The better blood pressure control achieved with these drugs makes it possible to treat the patient at home and reduce the risk of emergency delivery, but treatment does not seem to be mandatory for a good outcome of the pregnancy in cases of mild and moderate hypertension during pregnancy.
在一项开放性对照试验中，将美托洛尔和肼屈嗪联合治疗与妊娠期轻度和中度高血压的非药物治疗进行了比较。161名女性参与了该研究。药物治疗组的血压控制明显优于未给予抗高血压药物的组。由于母体或胎儿并发症，对照组早产引产的情况略为常见。治疗组有9名女性出现蛋白尿，对照组有5名。药物治疗组有3名婴儿围产期死亡，对照组有1名。两组新生儿的出生体重、头围和阿氏评分以及呼吸窘迫、心动过缓和低血糖的发生率相似。这些药物实现的更好的血压控制使得在家中治疗患者并降低紧急分娩的风险成为可能，但对于妊娠期轻度和中度高血压病例，治疗似乎并非妊娠取得良好结局的必要条件。
